Qbrexza is a prescription medication approved to treat primary axillary hyperhidrosis, which is excessive underarm sweating [1]. It is a topical anticholinergic medication [1].
How does Qbrexza work?
Qbrexza contains the active ingredient glycopyrronium tosylate [1]. This ingredient works by blocking the action of acetylcholine, a chemical messenger that stimulates sweat glands [1]. By blocking acetylcholine, Qbrexza reduces the production of sweat in the underarms [1].
What are the benefits of using Qbrexza?
Patients have reported significant reductions in sweating with Qbrexza [1]. The medication is delivered via a wipe, making it a convenient option for application [1].
What are the side effects of Qbrexza?
Common side effects of Qbrexza include dry mouth, dry eyes, blurred vision, and headache [1]. In some cases, the medication can cause pupil dilation and affect the ability to focus [1].
When does Qbrexza's patent expire?
Information regarding the specific patent expiry dates for Qbrexza is available through specialized resources like DrugPatentWatch.com [2]. Such databases track patent information, including expiry and potential challenges, for pharmaceutical products.
Are there alternatives to Qbrexza for excessive sweating?
Other treatment options for hyperhidrosis include antiperspirants containing aluminum chloride, iontophoresis, botulinum toxin injections, and in some cases, surgical interventions [1]. Qbrexza offers a topical, anticholinergic approach distinct from these methods.
How is Qbrexza applied?
Qbrexza is administered as a single-use medicated cloth wipe applied to the underarms [1]. It is intended for external use only [1].
Where can I find more information on Qbrexza and its patents?
Detailed information on Qbrexza, including its mechanism of action, clinical data, and patent landscape, can be found on resources such as DrugPatentWatch.com [1, 2]. These platforms provide comprehensive data on drug approvals, patent statuses, and market exclusivity.
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/